Payden & Rygel’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.6M | Buy |
14,670
+5,750
| +64% | +$5.87M | 1.35% | 28 |
|
|
2026
Q1 | $8.2M | Buy |
8,920
+5,900
| +195% | +$5.98M | 0.63% | 62 |
|
|
2025
Q4 | $3.25M | Sell |
3,020
-100
| -3% | -$95.6K | 0.22% | 72 |
|
|
2025
Q3 | $2.38M | Sell |
3,120
-12,600
| -80% | -$9.38M | 0.2% | 70 |
|
|
2025
Q2 | $12.3M | Hold |
15,720
| – | – | 1.01% | 44 |
|
|
2025
Q1 | $13M | Buy |
15,720
+6,200
| +65% | +$5.16M | 1.12% | 42 |
|
|
2024
Q4 | $7.35M | Sell |
9,520
-3,000
| -24% | -$2.48M | 0.63% | 66 |
|
|
2024
Q3 | $11.1M | Sell |
12,520
-11,700
| -48% | -$10.5M | 0.86% | 60 |
|
|
2024
Q2 | $21.9M | Sell |
24,220
-2,300
| -9% | -$1.84M | 1.77% | 12 |
|
|
2024
Q1 | $20.6M | Sell |
26,520
-3,400
| -11% | -$2.42M | 0.97% | 26 |
|
|
2023
Q4 | $17.4M | Hold |
29,920
| – | – | 1.21% | 36 |
|
|
2023
Q3 | $16.1M | Sell |
29,920
-800
| -3% | -$412K | 1.1% | 30 |
|
|
2023
Q2 | $14.4M | Sell |
30,720
-74,610
| -71% | -$31.3M | 1.02% | 44 |
|
|
2023
Q1 | $36.2M | Sell |
105,330
-14,570
| -12% | -$4.91M | 2.14% | 7 |
|
|
2022
Q4 | $43.9M | Sell |
119,900
-29,200
| -20% | -$10.4M | 2.34% | 3 |
|
|
2022
Q3 | $48.2M | Sell |
149,100
-3,600
| -2% | -$1.14M | 2.82% | 1 |
|
|
2022
Q2 | $49.5M | Sell |
152,700
-325
| -0.2% | -$97.6K | 2.97% | 1 |
|
|
2022
Q1 | $43.8M | Buy |
153,025
+5,100
| +3% | +$1.31M | 2.21% | 8 |
|
|
2021
Q4 | $40.9M | Sell |
147,925
-1,800
| -1% | -$456K | 1.89% | 10 |
|
|
2021
Q3 | $34.6M | Buy |
149,725
+32,500
| +28% | +$8.02M | 1.8% | 12 |
|
|
2021
Q2 | $26.9M | Buy |
117,225
+107,728
| +1,134% | +$21.6M | 1.28% | 34 |
|
|
2021
Q1 | $1.77M | Sell |
9,497
-231,103
| -96% | -$45.2M | 0.08% | 80 |
|
|
2020
Q4 | $40.6M | Hold |
240,600
| – | – | 2.08% | 9 |
|
|
2020
Q3 | $35.6M | Buy |
240,600
+7,300
| +3% | +$1.13M | 2.11% | 12 |
|
|
2020
Q2 | $38.3M | Sell |
233,300
-84,900
| -27% | -$13M | 2.44% | 5 |
|
|
2020
Q1 | $44.1M | Sell |
318,200
-23,256
| -7% | -$3.2M | 3.18% | 2 |
|
|
2019
Q4 | $44.9M | Buy |
341,456
+66,800
| +24% | +$7.74M | 2.81% | 2 |
|
|
2019
Q3 | $30.7M | Buy |
274,656
+8,360
| +3% | +$931K | 2.09% | 20 |
|
|
2019
Q2 | $29.5M | Buy |
266,296
+43,400
| +19% | +$5.11M | 2.02% | 16 |
|
|
2019
Q1 | $28.9M | Sell |
222,896
-5,704
| -2% | -$694K | 2.11% | 10 |
|
|
2018
Q4 | $26.5M | Buy |
228,600
+8,200
| +4% | +$916K | 2.13% | 11 |
|
|
2018
Q3 | $23.7M | Sell |
220,400
-2,700
| -1% | -$270K | 1.8% | 17 |
|
|
2018
Q2 | $19M | Hold |
223,100
| – | – | 1.5% | 33 |
|
|
2018
Q1 | $17.3M | Buy |
223,100
+27,200
| +14% | +$2.19M | 1.4% | 33 |
|
|
2017
Q4 | $16.5M | Hold |
195,900
| – | – | 1.44% | 29 |
|
|
2017
Q3 | $16.8M | Buy |
+195,900
| New | +$16.1M | 1.67% | 22 |
|
|
2015
Q3 | – | Sell |
-340
| Closed | -$28K | – | 158 |
|
|
2015
Q2 | $28K | Hold |
340
| – | – | ﹤0.01% | 129 |
|
|
2015
Q1 | $25K | Hold |
340
| – | – | ﹤0.01% | 144 |
|
|
2014
Q4 | $23K | Hold |
340
| – | – | ﹤0.01% | 145 |
|
|
2014
Q3 | $22K | Hold |
340
| – | – | ﹤0.01% | 144 |
|
|
2014
Q2 | $21K | Hold |
340
| – | – | 0.01% | 160 |
|
|
2014
Q1 | $20K | Buy |
340
+240
| +240% | +$13.4K | 0.01% | 151 |
|
|
2013
Q4 | $5K | Hold |
100
| – | – | ﹤0.01% | 216 |
|
|
2013
Q3 | $5K | Hold |
100
| – | – | ﹤0.01% | 199 |
|
|
2013
Q2 | $5K | Buy |
+100
| New | +$5.44K | ﹤0.01% | 197 |
|
Other funds holding LLY
Payden & Rygel's LLY Position: Q2 2026 in Review
Payden & Rygel increased its Eli Lilly (LLY) stake by 64% in Q2 2026, buying an estimated $5.87M and bringing the position to 14,670 shares worth $17.6M. The position accounts for 1.35% of the portfolio, ranked #28.
Payden & Rygel first reported a position in LLY in Q2 2013 and has held it in 45 quarters since. The position peaked at $49.5M in Q2 2022. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Payden & Rygel held 14,670 shares of Eli Lilly worth $17.6M as of Q2 2026.
- Payden & Rygel bought 5,750 Eli Lilly shares in Q2 2026, an estimated $5.87M.
- Eli Lilly made up 1.35% of Payden & Rygel's portfolio in Q2 2026, its #28 holding.
- Payden & Rygel first reported a position in Eli Lilly in Q2 2013 and has held it in 45 quarters since.
- Payden & Rygel's Eli Lilly position peaked at $49.5M in Q2 2022.
- 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Payden & Rygel's 13F filing for Q2 2026, filed 31 Jul 2026.